IRVINE, Calif.--(BUSINESS WIRE)--Immunis, Inc., a clinical-stage biotech developing novel secretomes for age-related diseases and immune dysfunction, has initiated non-terminal safety studies with VetBio Partners, LLC for canine muscle atrophy. With the preclinical success of Immunis’ investigational secretome (IMM01-STEM, previously IMMUNA) in aged mouse models and the rapidly advancing clinical testing in its STEM-MYO and STEM-META programs, Immunis is pursuing a parallel STEM-K9 program in dogs..

加利福尼亚州欧文市（商业新闻短讯）--Immunis，Inc.是一家临床阶段的生物技术公司，开发用于与年龄有关的疾病和免疫功能障碍的新型分泌蛋白组，已与VetBio Partners，LLC启动了针对犬类肌肉萎缩的非终末安全性研究。随着Immunis的研究性分泌蛋白组（IMM01-STEM，以前称为IMMUNA）在老年小鼠模型中的临床前成功，以及其STEM-MYO和STEM-META程序的临床测试迅速推进，Immunis正在寻求在狗中进行平行的STEM-K9程序。。

“We have an opportunity to do some good in the world with regards to animal health,” says Dr. Peter Canning, VetBio Partners’ Principal Consultant. “People are now thinking of their pets as members of the family. This has created a desire for people to maintain that relationship for as long as possible and to ensure that the quality of life for their pets is maintained well into their senior years.” With over three decades of experience in veterinary pharmaceutical product discovery and development, Dr.

VetBio Partners首席顾问彼得·坎宁（PeterCanning）博士说：“我们有机会在世界上为动物健康做点好事。”。“人们现在把宠物视为家庭的一员。这促使人们希望尽可能长时间地保持这种关系，并确保宠物的生活质量一直保持到老年。”博士拥有30多年的兽药产品发现和开发经验。

Canning will be an invaluable resource for Immunis throughout its preclinical trials..

在整个临床前试验中，罐头将成为Immunis的宝贵资源。。

As with humans, muscle atrophy in canines occurs because of age, inactivity and health conditions. There are limited studies on muscle wasting in dogs, despite there being a strong negative correlation between canine age and lean muscle mass. Muscle loss also contributes to congestive heart failure, chronic kidney disease, cancer, and osteoarthritis (OA)..

与人类一样，由于年龄，不活动和健康状况，犬科动物的肌肉萎缩会发生。尽管犬的年龄和瘦肌肉质量之间存在强烈的负相关，但关于犬肌肉萎缩的研究有限。肌肉萎缩也会导致充血性心力衰竭，慢性肾病，癌症和骨关节炎（OA）。。

“Our approach for the animal studies mirrors the rigorous standards we apply in our human clinical trials,” explains Dr. Hans Keirstead, Chairman of Immunis. “We’re committed to advancing care for canines as we are doing for humans, in a responsible and carefully controlled manner, with the ultimate goal of improving mobility and quality of life.” The non-terminal nature of the study ensures the ethical treatment of all our canine participants..

“我们的动物研究方法反映了我们在人体临床试验中应用的严格标准，”Immunis主席Hans Keirstead博士解释道。“我们致力于以负责任和精心控制的方式推进对犬科动物的护理，就像我们对人类所做的那样，最终目标是提高移动性和生活质量。”这项研究的非终端性质确保了我们所有犬科动物参与者的道德待遇。。

Immunis’ expansion into animal health underlines the company’s commitment to translating its innovative therapies across species, potentially opening new avenues for treating age-related conditions in both humans and their companion animals.

Immunis在动物健康领域的扩张突显了该公司致力于跨物种转化其创新疗法，有可能为治疗人类及其伴侣动物的年龄相关疾病开辟新途径。

About VetBio Partners

关于VetBio合作伙伴

VetBio Partners, LLC is a privately held firm providing research and development consulting services to human health biopharmaceutical companies with technologies that have potential animal health applications. Leveraging our network of contract research organization partners and 35+ years of experience with all phases of drug discovery and development of animal health products enables efficient assessment of the efficacy and safety of new technologies and advancement of client programs.

VetBio Partners，LLC是一家私营公司，为人类健康生物制药公司提供具有潜在动物健康应用技术的研发咨询服务。利用我们的合同研究组织合作伙伴网络和35年以上在药物发现和动物保健产品开发各个阶段的经验，可以有效评估新技术的功效和安全性以及客户计划的推进。

We also provide support for business development activities through our contacts within major animal health pharmaceutical companies..

我们还通过与主要动物保健制药公司的联系，为业务发展活动提供支持。。

About Immunis Inc.

关于Immunis Inc。

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations.

Immunis是一家私营生物技术公司，开发了一种新型免疫调节分泌蛋白产品，用于治疗年龄和疾病相关免疫衰退的各种表现。。

For additional information about Immunis’ clinical trials please visit: https://immunisbiomedical.com/clinical-trials/.

有关Immunis临床试验的更多信息，请访问：https://immunisbiomedical.com/clinical-trials/.

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性声明的警示说明

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts.

本通讯包含构成1995年《私人证券诉讼改革法案》（如适用）所指的“前瞻性声明”的声明。前瞻性陈述包括但不限于关于我们的计划、信念、期望和假设的陈述，以及不一定是历史事实的其他陈述。

You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication.

请注意，这些前瞻性陈述只是预测，涉及风险和不确定性。此外，任何前瞻性声明仅在作出之日起生效，我们不打算更新或修订任何前瞻性声明。本通讯还包含与我们的业务和行业相关的市场数据，其中包括基于我们认为合理且对截至本通讯日期的预测最重要的几个假设的预测。

If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein..

如果我们的任何假设被证明不正确，我们的实际结果可能与基于这些假设的预测有很大差异。本通信既不是出售要约，也不是购买本文所述任何证券的要约。。